AntagomiR-192-5p-engineered exosomes encapsulated in MXene-modified GelMA hydrogel facilitated epithelization of burn wounds by targeting OLFM4
Quick Facts
- Publication title: AntagomiR-192-5p-engineered exosomes encapsulated in MXene-modified GelMA hydrogel facilitated epithelization of burn wounds by targeting OLFM4
- Journal: Bioact Mater
- Year: 2025
- DOI: 10.1016/j.bioactmat.2025.06.013
- PMID/PMCID: 40575328; PMC12198005
Research overview
In this study we screened the key miRNA regulating the epithelialization process under oxidative stress conditions through high-throughput sequencing. In this study we screened the key miRNA regulating the epithelialization process under oxidative stress conditions through high-throughput sequencing.
Key findings
Burn wound healing is a multifaceted process often complicated by excessive inflammation and impaired keratinocyte function, both of which are key factors contributing to delayed healing.
In this study we screened the key miRNA regulating the epithelialization process under oxidative stress conditions through high-throughput sequencing.
We identified that miR-192-5p was significantly upregulated in both oxidative stress models of keratinocytes and burn wound tissues, with detrimental effects on keratinocyte proliferation, migration, and apoptosis.
Inhibition of miR-192-5p enhanced epidermal cell function by upregulating olfactomedin-4 (OLFM4), a key gene associated with cell proliferation, adhesion and migration.
Echo Biotech Role
Echo Biotech contributed EV material/reference-material supply; the study also used or cited ContrExo®.
Related platforms: EV Materials / Reference Materials, Research Reagents & Tools
Related services and capabilities: EV Material / Reference Material Supply
Related products or reagents: ContrExo® EV Reference Material
References
Original publication: AntagomiR-192-5p-engineered exosomes encapsulated in MXene-modified GelMA hydrogel facilitated epithelization of burn wounds by targeting OLFM4 Bioactive Materials. 2025. DOI: 10.1016/j.bioactmat.2025.06.013. PMID/PMCID: 40575328; PMC12198005.